ArnbergN. (2012). Adenovirus receptors: Implications for targeting of viral vectors. Trends Pharmacol. Sci., 33, 442–448.
2.
BarouchD.H., LiuJ., LiH., et al. (2012). Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 482, 89–93.
3.
CrystalR. (2014). Adenovirus: The first effective in vivo gene delivery vector. Hum. Gene Ther., 25, 3–11.
4.
EwerK.J., O'HaraG.A., DuncanC.J.A., et al. (2013). Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun.4.
5.
GaggarA., ShayakhmetovD.M., and LieberA. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med., 9, 1408–1412.
6.
KalyuzhniyO., Di PaoloN., SilvestryM., et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. USA, 105, 5483–5488.
7.
RaperS.E., ChirmuleN., LeeF.S., et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80, 148–158.
8.
SalinasS., SchiavoG., and KremerE.J. (2010). A hitchhiker's guide to the nervous system: the complex journey of viruses and toxins. Nat. Rev. Microbiol., 8, 645–655.
XuZ., QiuQ., TianJ., et al. (2013). Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med., 19, 452–457.
